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Abstract
Depression is associated with more rapid cognitive decline in Parkinson’s disease (PD). The goal of
this study was to examine the impact of the acute (8-week) and longer-term (24- week) antidepressant
treatment on cognition in PD and to detail cognitive predictors of treatment response. Fifty-two
depressed PD patients were enrolled in an NIH funded randomized-controlled trial of nortriptyline,
paroxetine, and placebo. Neuropsychological testing was performed at baseline, and weeks eight and
twenty-four. Higher baseline scores on measures of executive functioning, speed of processing, and
verbal memory were associated with antidepressant response. Treatment responders did not exhibit
larger gains in cognition than non-responders. Findings warrant replication.
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Parkinson’s disease (PD) is the second most common neurodegenerative disease in the US,
affecting over 1 million individuals. While the motor symptoms that define the illness, such
as tremor, rigidity, and postural imbalance, have received a great deal of attention, the non-
motor aspects of this condition are increasingly focused upon. Depression, one of the most
prevalent non-motor complications in PD {1}, impacts as many as 50% of patients {2,3}. The
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high prevalence of depression in PD is of great clinical significance as it has a documented
negative impact on quality of life, self-care, family relationships, and physical disability {4,
5,6}.
Moreover, depression has been linked to more severe and more rapidly progressive cognitive
decline in PD {7}. For example, difficulties with memory, attention, language, and executive
functions have been frequently observed in PD and are often exacerbated by depression,
especially when that depression is pronounced {8,9,10,11}. Of these various cognitive abilities,
memory, and to a lesser extent language (i.e., verbal fluency and naming), appear to be the
most severely affected by depression {2,3,8,9,10,12}. While these cognitive changes are
independently detrimental to the patient’s well-being {13} and have been found to predict non-
response to psychopharmacological treatment in the aged {14,15,16}, they also further
intensify the social, occupational, and functional impairment caused by both PD and
depression.
Despite the deleterious impact of depression in PD (dPD), there are few well-designed
treatment outcome studies that can guide clinical care. Moreover, few studies have investigated
the impact of antidepressant treatment on the various aspects of cognitive functioning in PD,
or the extent to which cognition affects antidepressant treatment response in this population
{17,18}. In an NIH-funded, randomized, double-blind trial of nortriptyline, paroxetine and
placebo for the treatment of dPD, we have recently demonstrated that nortriptyline was superior
to placebo for the acute treatment of depression over an 8- week period {19} and that both
active drugs were superior to placebo for the prevention of relapse over a 24-week period
{20}. The purpose of this paper is to describe the neuropsychological findings obtained after
the acute and longer-term treatment of depression in this randomized controlled trial, and to
detail cognitive predictors of treatment response.
Method
Overview
This randomized controlled double-blind trial of nortriptyline, paroxetine, and placebo had 2
phases; an 8-week acute treatment phase and a 4 month extension phase. In the acute treatment
phase, clinical response was defined a priori as a 50% reduction in baseline to endpoint score
on the Hamilton Depression Rating Scale (HAM-D) {21}. However, patients were eligible to
enter the extension phase of the study if they were rated at least minimally improved on the
Clinical Global Impression Improvement Scale {22} (i.e., CGI-I rating of 1, 2, or 3) at the end
of the acute treatment phase and wished to continue with blinded treatment. The results of
neuropsychological testing obtained across both phases of this trial are detailed below. The
study had the full approval of UMDNJ-Robert Wood Johnson Medical School IRB. All patients
signed a statement of informed consent prior to the initiation of any study procedures.
Participants
Patients were recruited from the movement disorders clinic at Robert Wood Johnson Medical
School, the New Jersey Chapter of the APDA, and local print media. All participants received
free study medication and evaluation sessions, and $20 for each completed study visit.
Fifty-two patients (27 male, 25 female; age 35–80) with a confirmed diagnosis of PD based
on research criteria {23} and a primary diagnosis of major depression or dysthymia based on
the Structured Clinical Interview (SCID) {24} for the Diagnostic and Statistical Manual of
Mental Disorders 4th ed. (DSM-IV) {25} were enrolled in the acute phase of the treatment
trial. Patients with cognitive impairment (MMSE {26} less than 26), “off time” greater than
50% of the day, any comorbid DSM-IV Axis I diagnosis other than an anxiety disorder, or who
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had failed two or more adequate trials (dose and length) of an approved antidepressant were
excluded from participation. Using additional psychotropic medications other than the study
drug was prohibited. Patients maintained a stable dose of their PD medication throughout the
trial. All evaluations were completed in the “on” state.
Thirteen additional patients signed consent but did not qualify for participation due to failure
to meet the inclusion/exclusion criteria described above. Of the 52 patients who were enrolled,
20 met the a priori criteria for entry into the extension phase of the study (i.e., CGI-I of 1,2, or
3) and chose to continue blinded treatment.
Measures
Cognition was assessed with a battery of neuropsychological tests designed to evaluate the
aspects of cognitive functioning that may be affected in PD. These included theforward and
backward digit span subtests of the Wechsler Adult Intelligent Test-Third Edition (WAIS-III)
{27}, which assesses auditory attention; the word list recall and recognition subtests of the
Wechsler Memory Scale-Third Edition (WMS) {28}, which measure verbal memory; the
Boston Naming Test (BNT) {29} and verbal category fluency test (animal naming) which
assess different aspects of language; and the Stroop Color-Word test {30}, a measure of both
processing speed and executive function (i.e., set switching).
Measures of depression (HAM-D; CGI-I), anxiety (Hamilton Anxiety Rating Scale-HAM-A
{31}), sleep (Pittsburgh Sleep Quality Index- PSQI {32}), quality of life (Medical Outcome
Study Short Form - SF-36 {33}; Parkinson’s Disease Questionnaire- PDQ-8 {34}), and motor
functioning (Unified Parkinson’s Disease Rating Scale- UPDRS {35}) were also administered
over the course of the trial.
Procedure
Preliminary screening was conducted by telephone. Appropriate individuals were scheduled
for an in-person evaluation where a detailed medical and psychiatric history was obtained via
clinical and semi-structured interviews (SCID), a motor exam was performed (UPDRS), and
baseline assessments of depression and anxiety were administered (HAM-D, HAM-A).
Patients also completed a packet of self-report measures (PSQI, PDQ-8, SF-36) and a battery
of neuropsychological tests (MMSE, Digit Span, recall and recognition subtests of the WMS,
Stroop, animal naming, and BNT).
Eligible individuals were randomized, in variable length blocks, to receive equivalent-
appearing nortriptyline, paroxetine CR or placebo. Dosing was flexible (based on ranges typical
for a geriatric population) and decisions on dose were made at each visit based on efficacy and
tolerability, or between visits if the patient was having troublesome side effects (i.e., dry mouth,
insomnia). The minimum to maximum doses of study drug were as follows: paroxetine CR
12.5 mg to 37.5 mg; nortriptyline 25mg to 75 mg; placebo 1–3 pills. All patients were instructed
to take a single daily dose of the study medication in the evening. All study personnel were
blind to group assignment. Neuropsychological testing, and the assessments of depression,
anxiety, motor function, sleep, and quality of life were re-administered at the end of the acute
(week 8) and extension phases of the study (week 24).
Results
Data was analyzed using SPSS version 15 for Windows. All tests were two-tailed. Data analysis
included all patients who had a baseline and at least one follow-up neuropsychological
assessment. The results presented below detail the impact of successful antidepressant
treatment on cognition in PD, and cognitive predictors of treatment response. The impact of
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antidepressant treatment on mood, quality of life, and motor functioning are detailed elsewhere
{19, 20}.
Fifteen patients (28.8%) were treatment responders (>50% reduction from baseline to week 8
HAM-D) while 37 patients (71.2%) were classified as non-responders. In addition to
comparing the impact of treatment response and non-response on cognition, several additional
between group comparisons are reported below. In all of these analyses, the most impaired
subgroup or quartile (i.e., highest scores for depression or disease severity; lowest score for
memory or executive function) is compared to the rest of the sample. We chose this grouping
so that the whole sample could be included in the analyses and because we were most interested
in understanding the differences between patients with more severe levels of disease pathology
versus those with lower levels of symptomatology.
Baseline Data
Of the 52 patients enrolled in the trial, 48 had a diagnosis of major depression. Two patients
were diagnosed with double depression (dysthymia in addition to major depression), while 2
had only dysthymia. Eighty percent of the cases of major depression were recurrent in nature.
The mean age of the sample was 62.2 (SD=8.7), the mean duration of PD was 6.6 years
(SD=5.9), the average age of onset was 56 (SD=9.5), and the mode of the sample with regard
to stage of illness (Hoehn-Yahr scale) was 2. The average dose of medication was 28.4 mgs
for paroxetine CR, 48.5 mgs for nortriptyline (with a mean nortriptyline level of 74.88) and
2.7 pills for placebo.
Mean baseline scores on neuropsychological measures of attention, memory, and language all
fell within the average range in this sample. The sample as a whole scored well below average
on the Word and Color subscales (speed of processing) of the Stroop test. Because patients
were so impaired in these areas, no Stroop effect was observed (i.e., mean scores on Color-
Word, the executive function portion of the task, were higher than mean scores on the Word
and Color subscales). See Table 1. In addition, one-way ANOVAs indicated that there were
no significant differences between drug groups on any of the baseline neuropsychological
measures (p values range from .17 to .98).
Baseline cognition, depression, and duration of PD—Exploratory t-tests were
conducted to compare the neuropsychological test results of patients who scored in the top
quartile for depression (i.e., most depressed; HAM-D >22) to those with ratings in the bottom
three quartiles (HAM-D range of 10–21). While there was no significant difference between
patients with higher versus lower depression on the MMSE (p=.89), patients with higher levels
of depression performed significantly worse on baseline measures of language (Boston naming,
t(49)=−2.35, p=.02; category fluency, t(49)=−3.32, p=.002) and memory (recall, t(49)=−1.97,
p=.05; delayed recall, t(49)=−2.20, p=.03) compared to those with less severe depression
ratings.
Exploratory t-tests also indicated that longer (top quartile 10–20 years) vs. shorter (bottom 3
quartiles 1–9 years) duration of PD was associated with poorer performance on both the Word
subscale of Stroop (speed of processing; t(49)=−2.87, p=.006) and composite Stroop test score
(speed of processing and executive functions [attention/response inhibition]; t(50)= −2.05, p=.
05). However, there was no significant difference in baseline depression scores between
patients who had PD for a longer vs. shorter period of time (p=.81). In addition, no significant
difference in baseline depression was found between those who scored highest (top quartile)
versus lower (bottom 3 quartiles) on the measures of disease severity (UPDRS total and motor
subscale scores, p=.59 and .10, respectively).
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Baseline cognition and response to treatment—Exploratory t-tests indicated that
treatment responders(> 50% reduction in baseline to week 8 HAM-D score) had significantly
higher baseline scores (i.e., were less impaired) on measures of speed of processing/executive
functioning (Stroop composite score, t(50)=2.80, p=.007; Stroop Word, t(49)=2.45, p=.018;
Stroop Color, t(49)=2.53, p=.015; Stroop Word-Color, t(49)=1.89, p=.07) and memory
(composite score reflecting word list recall, delayed recall, and recognition, t(50)=2.05, p=.
046; individual memory subscales ns).
Acute Phase of Treatment
Neuropsychological predictors of acute treatment response—Because patients
who were treatment responders in the acute phase had significantly higher baseline scores on
measures of both speed of processing/executive functioning and memory, we used logistic
regression to examine if higher (top three quartiles; better performance) vs. lowest (bottom
quartile; poorest performance) scores in these cognitive domains were predictive of treatment
response, when considering potential confounding variables. When controlling for baseline
depression (HAM-D), age, duration of PD, and the effect of drug (also a significant predictor),
a “higher” Stroop composite score at baseline remained a significant predictor of treatment
response (Wald χ2(1)=4.07, p=.04; OR=10.96). A “higher” baseline composite memory score
(Wald χ2(1)=.478, p=.49, OR=1.81) however, was not a significant predictor of treatment
response when controlling for the aforementioned variables. See Table 2.
Effect of depression treatment response on cognition—Repeated Measures
ANOVA indicated that there were no significant group (responder status; > 50% reduction in
baseline to week-8 HAM-D score) by time interactions on any of the neuropsychological
measures in the acute treatment phase (p values range from .10 to .889). Therefore, depression
“responders” did not demonstrate larger improvements in cognition than non-responders. In
addition, there was no correlation between change in patients’ HAM-D scores and change in
their performance on any neuropsychological measure between baseline and week 8 (p values
range from .55 to .78). Extension Phase of Treatment Because only twenty patients entered the
extension phase of the study, there was not sufficient power to examine neuropsychological
predictors of long-term treatment response or to compare differences between responders and
non-responders in this phase of treatment. However, we did examine the impact of longer-term
treatment of depression on cognition for all patients who met the criteria to enter the extension
phase of the study (at least minimally improved on the CGI-I after 8 weeks of treatment).
Results of Repeated Measures ANOVA suggested that patients who entered the extension
phase of the study demonstrated significant improvements in verbal memory (composite score,
F(2,17)=7.93, p=.004; word recall, F(2,16)=9.12, p= .002; word recognition, F(2,16)=5.50,
p=.02; word delayed recall, F(2,16)=6.09, p=.01), and one test of language (BNT, F(2,16)
=6.37, p=.009) over the course of the study. Planned contrasts indicated that significant
improvements in the verbal memory composite score (F(1,18)=16.70, p=.001) and immediate
recall (F(1,17)=16.97, p=.001) were evident by the end of the acute phase and maintained
throughout the end of the extension phase (composite, F(1,18)=7.72, p=.01; recall, F(1,17)
=6.26, p=.023). Gains specific to delayed recall (F(1,17)=12.36, p=.003) and recognition (F
(1,17)=11.40, p=.004) were observed at week 8, but week 24 scores on these domains were
not significantly different from baseline (.10 and .15, respectively). Improvements on the
Boston Naming Test, however, were not apparent until the extension phase of the study (F
(1,17)=13.05, p=.002) (i.e., no change between baseline and week 8, but significant change
noted between baseline and week 24). No notable changes were observed in a second test of
language (verbal fluency-animal naming, p=.257), or measures of attention (digit span, p=.
386) or executive function (Stroop, p values range from .258 to .692).
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Effect of Drug on Cognition- Acute and Extension Phase
Repeated Measures ANOVA indicated that there were no significant group (drug) by time
interactions on any of the neuropsychological measures in either the acute (p values range
from .10 to .89) or follow-up period (p values range from .15 to .90). Therefore, neither
paroxetine, nortriptyline, nor placebo were associated with either an improvement or worsening
of cognitive functioning in either short or longer-term treatment.
Discussion
This is one of few studies to examine the impact of antidepressant treatment on cognition in
patients with Parkinson’s disease and depression. Overall, results indicated that higher baseline
scores on measures of speed of processing and executive functions (Stroop) predicted acute
treatment response, even when controlling for confounding factors such as age, duration of
PD, baseline depression, and the effect of drug (with nortriptyline superior to placebo for the
acute treatment of depression as detailed elsewhere {19, 20}). However, while these aspects
of cognitive functioning appeared to predict short-term treatment response in this population,
no area of cognition was found to improve as a result of successful antidepressant treatment
after the end of the 8-week acute phase. Patients who demonstrated “response” to
antidepressant treatment scored higher on baseline measures of cognition (i.e., verbal memory,
speed of processing, executive functioning), compared to patients who did not respond, but
their scores did not improve over the course of treatment. Moreover, neither paroxetine nor
nortriptyline appeared to have negative effects on cognition in the context of short (8 weeks)
and longer-term (24 weeks) antidepressant treatment. Finally, consistent with past cross-
sectional studies {8,9,10,11,12}, more severe depression was associated with poorer
performance on baseline tests of memory and language and no Stroop effect was observed
{36,37}.
There are few studies with which to compare these results in PD. In one of the limited studies
conducted within the dPD population, Weintraub et al. also found higher baseline scores of
verbal memory to be associated with increased rates of treatment response with escitalopram,
and that treatment “response” was not associated with any type of improvements across a
variety of cognitive domains {17}. However, in contrast to our study, these authors did not
find an effect for either baseline psychomotor speed or executive functions on treatment
outcome. Yet, the small sample size and limited rates of response in Weintraub et al.’s study
make it difficult to aggregate these findings. In addition, dopamine agonists, such as
pramipexole, have been shown to have negligible effects on working memory and attention in
dPD, despite their potential antidepressant effects {18}.
Several of our findings are also consistent with the geriatric depression literature. For example,
speed of processing, verbal memory, and executive functions have been found to be predictive
of antidepressant treatment response in several studies in the aged {14,15,16}. While research
concerning change in cognitive status is mixed, some studies have indicated that efficacious
antidepressant treatment is not associated with cognitive gains in the elderly {38,39,40}.
Furthermore, one study found that older patients with little cognitive impairment prior to
treatment did not experience cognitive gains following antidepressant therapy whereas patients
who were more impaired did exhibit improvements following treatment {40}.
Therefore, one possibility for our finding that responders did not improve more than non-
responders on neuropsychological measures after acute treatment may be the fact that patients
did not demonstrate gross impairments on the neuropsychological measures at baseline (with
the exception of Stroop). This pattern of average baseline performance and lack of change over
time is consistent with that observed by Rektorova et al. in their study investigating the efficacy
of dopamine agonists on depression and cognition in PD {18}. It is also likely that both the
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small sample size, the limited range of scores observed on many of the neuropsychological
measures (potentially because the majority of our patients presented in the earlier stages of
PD), and the mild to moderate levels of depression reported by the majority of the sample (as
more severe depression has a greater deleterious impact on cognition {41}) restricted our ability
to detect cognitive changes between responders and non-responders.
Alternatively, it is possible that the neuroanotomical changes that characterize PD (i.e.,
degeneration of dopaminergic cells in the substantia nigra, dysfunction of cortico-striatal
circuits instrumental in frontal brain functions, and presence of diffuse Lewy bodies {13}) are
the main contributor to the cognitive deficits observed in this population. For example, because
Stroop score, (predictive of treatment response), was associated with PD duration but not
depression at baseline, poor Stroop performance may be more sensitive to PD than depression
{42}. As a result, poor performance on this test may index more severe disease and widespread
neuropathology, making treatment response less likely for this reason. For the same reason,
and because poor performance on select cognitive tasks (such as Stroop) may not be related to
depression, successful treatment of dPD may exert minimal impact on certain aspects of
cognition (i.e., executive functions, speed of processing) as it cannot reverse the structural brain
changes inherent in the disease process.
Limited conclusions may be drawn from the extension phase data given the small sample size
and lack of power needed to make between group comparisons. Yet, it is interesting to note
that improvements in language (i.e., naming) were not observed until the extension phase of
the trial for patients who opted to continue with blinded treatment. This finding may suggest
that longer term treatment of depression may lead to sustained improvement in this cognitive
domain. However, in the absence of a comparison condition (all patients who entered the
extension phase were at least partially improved, though not necessarily “responders”),
interpretation of this finding is difficult and the role of practice effects, though thought to be
small in PD {43}, can not be dismissed.
In conclusion, our findings suggest that higher baseline performance on measures of executive
functioning, speed of processing, and verbal memory was associated with antidepressant
treatment response in PD. However, “responder status” was not linked with any improvements
or changes in cognitive status during the acute phase of treatment. Improvements in language
noted during the extension phase must be interpreted with caution given the absence of a
comparison condition. As this is one of few studies examining the impact of treatment of
depression on cognition in PD, further research is needed to replicate these findings.
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Table 1
Means (T-scores) and Standard Deviations for Baseline Neuropsychological Measures
Measure Mean Standard Deviation
Digit Span 53.65 8.91
WMS Immediate Recall 46.16 11.52
WMS Delayed Recall 55.57 7.83
WMS Recognition 52.14 8.60
Boston Naming Test 48.49 15.10
Category Fluency 53.59 11.33
Stroop Word 34.96 14.31
Stroop Color 33.92 11.12
Stroop Color-Word 42.67 12.86
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Table 2
Logistic Regression- Predictors of Treatment Response
Wald χ2 p-value Odds Ratio
Stroop
 Baseline HAM-D 0.60 .44
 Age 1.07 .31
 Duration of PD 0.35 .55
 Drug ** 7.84 .02
(Paxil v. Placebo) 0.91 .34 .37
(Nortriptyline v. Placebo) 3.66 .06 5.14
 Stroop Higher v. Lowest 4.07 .04 10.96
Memory
 Baseline HAM-D 1.70 .19
 Age 1.38 .24
 Duration of PD 0.25 .62
 Drug 7.69 .02
(Paxil v. Placebo) 1.23 .27 .31
(Nortriptyline v. Placebo) 3.12 .08 4.16
 Memory Higher v. Lowest .48 .49 1.81
**
Please note that drug is also a significant predictor of treatment response as detailed in prior publications (19, 20), with higher response rates noted
amongst patients taking nortriptyline vs. placebo. Baseline Stroop score remained a significant predictor of treatment response even when controlling
for this variable.
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